ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

4:00PM-5:30PM: Abstract Number: 0854

Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis

Abstracts: Vasculitis – ANCA-Associated I

4:00PM-5:30PM: Abstract Number: 0842

Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:30PM: Abstract Number: 0851

Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0833

Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort

Abstracts: Pediatric Rheumatology – Clinical I: JIA

4:00PM-5:30PM: Abstract Number: 0794

Microbiota-dependent Indole Production Is Required for the Development of Collagen-induced Arthritis

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0849

Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0804

Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:00PM: Abstract Number: PP16

Peer Health Coaches Help Scleroderma Patients Cope with Isolation

Patient Perspectives

4:00PM-5:30PM: Abstract Number: 0848

Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0850

Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0843

Predictive Validity of Data-driven Definitions for Active and Structural Lesions in the SI Joints Typical for Axial SpA: A 2-year Follow-up in the SPondyloArthritis Caught Early Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:30PM: Abstract Number: 0846

Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB – GRB2/ERK/RUNX2 Pathway

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:00PM: Abstract Number: PP14

Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease

Patient Perspectives

4:00PM-5:30PM: Abstract Number: 0820

Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0858

Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].